Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hedley Carr

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Scientific Reports|September 4, 2019
Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNAVicky Rowlands, Andrzej J Rutkowski, Elena Meuser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancerCarmela Ciardullo, Luis Tobalina, T Hedley Carr, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2015
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291Kenneth S Thress, Roz Brant, T Hedley Carr, et al.
Nature Reviews. Cancer|April 27, 2016
Defining actionable mutations for oncology therapeutic developmentT Hedley Carr, Robert McEwen, Brian Dougherty, et al.
Plos One|July 11, 2013
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibJames R Bradford, Matthew Farren, Steve J Powell, et al.
Peerj|April 11, 2017
Prioritisation of structural variant calls in cancer genomesMiika J Ahdesmäki, Brad A Chapman, Pablo Cingolani, et al.
Cancers|November 27, 2021
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerT Hedley Carr, Carrie Adelman, Alan Barnicle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 20, 2019
Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLCSumitra Mohan, Victoria Foy, Mahmood Ayub, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialCostanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.
Human Mutation|December 8, 2017
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practiceGillian Ellison, Miika Ahdesmäki, Sally Luke, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Scientific Reports|September 4, 2019
Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNAVicky Rowlands, Andrzej J Rutkowski, Elena Meuser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancerCarmela Ciardullo, Luis Tobalina, T Hedley Carr, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2015
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291Kenneth S Thress, Roz Brant, T Hedley Carr, et al.
Nature Reviews. Cancer|April 27, 2016
Defining actionable mutations for oncology therapeutic developmentT Hedley Carr, Robert McEwen, Brian Dougherty, et al.
Plos One|July 11, 2013
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibJames R Bradford, Matthew Farren, Steve J Powell, et al.
Peerj|April 11, 2017
Prioritisation of structural variant calls in cancer genomesMiika J Ahdesmäki, Brad A Chapman, Pablo Cingolani, et al.
Cancers|November 27, 2021
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerT Hedley Carr, Carrie Adelman, Alan Barnicle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 20, 2019
Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLCSumitra Mohan, Victoria Foy, Mahmood Ayub, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialCostanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.
Human Mutation|December 8, 2017
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practiceGillian Ellison, Miika Ahdesmäki, Sally Luke, et al.
Pageof 2